Krystal BiotechFRA:4KB +2.29%58 Net Margin % is 48.07% as of Mar. 2026, which is 57% above its 10-year median of 30.69. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €263.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 946 Biotechnology companies, Krystal Biotech ranks better than 95.67% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Krystal Biotech's Net Income for the
three
months ended in Mar. 2026 was €48.4 Mil. Krystal Biotech's Revenue for the
three
months ended in Mar. 2026 was €100.6 Mil. Therefore, Krystal Biotech's net margin for the quarter that ended in Mar. 2026 was 48.07%.
The historical rank and industry rank for Krystal Biotech's Net Margin % or its related term are showing as below:
FRA:4KB'
s Net Margin % Range Over the Past 10 Years
Min: 21.56 Med: 30.69 Max: 53.93
Current: 53.93
FRA:4KB's Net Margin % is ranked better than 95.67% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:4KB: 53.93
Krystal Biotech (FRA:4KB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Krystal Biotech Net Margin % Related Terms
Krystal Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Net Margin % Comparison
For the Biotechnology subindustry, Krystal Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Net Margin % of 48.07% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Krystal Biotech and its competitors. This is 57% above median its historical median of 30.69. Over the past decade, Krystal Biotech's Net Margin % has ranged from 21.56 to 53.93. According to the industry distribution chart, Krystal Biotech ranks #41 out of 946 companies in the Biotechnology industry, placing it in the top 4.3%.
Is Krystal Biotech's Net Margin % too high?
Krystal Biotech's current Net Margin % of 48.07% is 57% above median its 10-year median of 30.69. Over the past 10 years, this metric has ranged from a low of 21.56 to a high of 53.93. Based on the distribution chart, Krystal Biotech ranks #41 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Net Margin % compare to NUVL and PRAX?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #41 out of 946 companies for Net Margin %. This places Krystal Biotech in the top 4% of its industry — outperforming the majority of peers. Historically, Krystal Biotech's own Net Margin % has ranged from 21.56 to 53.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Net Margin % is 48.07%, which is 57% above median its own 10-year median of 30.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €263.13, compared to a current price of €303.60 — trading 15.4% above its estimated fair value. The current Net Margin % is 48.07%, which is 57% above median its 10-year median of 30.69. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Net Margin % is 48.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Net Margin %: 48.07% (57% above median its 10-year median of 30.69)
GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
